Trimethyl-[2-(1,3,7-trimethyl-2,6-dioxopurin-8-yl)oxyethyl]azanium

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: Trimethyl-[2-(1,3,7-trimethyl-2,6-dioxopurin-8-yl)oxyethyl]azanium
• 化学式: C13H22N5O3+
• 分子量: 296.35
• InChiKey: QLNXAEBEIYXOMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  67.7
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS<br/>[FR] PYRIMIDINES INHIBITRICES DE CHK-, PDK- ET DE AKT, PRODUCTION ET UTILISATION DE CES COMPOSES COMME AGENTS PHARMACEUTIQUES
  申请人：SCHERING AG

  公开号：WO2004048343A1

  公开（公告）日：2004-06-10

  This invention relates to pyrimidine derivatives of general formula (I) as inhibitors of kinases, their production as well as their use as medications for treating various diseases.

  这项发明涉及通式（I）的嘧啶衍生物作为激酶抑制剂，它们的生产以及它们作为治疗各种疾病的药物的用途。
• Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
  申请人：——

  公开号：US20040186118A1

  公开（公告）日：2004-09-23

  This invention relates to pyrimidine derivatives of general formula (I) as inhibitors of kinases, their production as well as their use as medications for treating various diseases

  本发明涉及一种通式（I）的嘧啶衍生物，作为激酶抑制剂，其制备以及它们作为治疗各种疾病的药物的用途。
• CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS
  申请人：Schering Aktiengesellschaft

  公开号：EP1565446A1

  公开（公告）日：2005-08-24